Triflusal vs Acetylsalicylic Acid in Secondary Prevention of Cerebral Infarction "TACIP"

Completed

Phase 3 Results

Trial Description

To compare the safety and efficacy of triflusal vs aspirin in secondary stroke prevention.

Interventions

  • Aspirin (stroke prevention) Drug
    Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
  • Triflusal (Disgren)Drug
    Other Names: DisgrenĀ®
    Intervention Desc: Antiplatelet agent structurally related to aspirin

Trial Design

Randomized, double-blind, multicenter parallel trial involving 2113 patients at 43 centers.

Patient Involvement

Patients were randomized to receive either trifusal (600 mg OD) or aspirin (325 mg OD) administered for up to 3 years. Mean follow-up of 30 months.

Outcomes

Type Measure Time Frame Safety Issue
Primary Combined incidence of cardiovascular death, non-fatal stroke or non-fatal AMI.

Sponsors

J. Uriach & Cia., Spain and Technifar S.A.